DR. PRATHAP C REDDY, FOUNDER AND CHAIRMAN – APOLLO HOSPITALS INAUGURATES SOUTH ASIA’S FIRST DIGITAL PET-CT AT THE APOLLO PROTON CANCER CENTRE, CHENNAI

Date: 2019-05-27 | Location: Chennai

---

The state-of-the-art Digital PET CT - Biograph Vision 600™ scanning machine is a radioactive diagnostic agent used in positron emission tomography (PET) imaging. The inauguration was done in the presence of Dr. Prathap C Reddy, Founder and Chairman – Apollo Hospitals, Ms. Suneeta Reddy, Managing Director, Apollo Hospitals Group and Mr. Vivek Kanade, Executive Director, Siemens Healthineers India.

With nearly a million new cancer cases diagnosed per annum in India, staging disease more accurately and defining treatment strategies better is the need of the hour. With the introduction of Biograph Vision 600™ in India, will help deliver the right treatment to the right patient and at the right time.

“Biograph Vision 600™ is designed for improved accuracy, performance, and reproducibility to deliver a whole new world of precision in PET/CT imaging. With the market’s fastest time-of-flight and highest effective sensitivity, Biograph Vision™ helps reduce scan time and injected dose, reducing patient exposure to radiation.

PET CT is indispensable as a diagnostic and prognostic tool in the assessment of patient response to cancer therapy and cancer recurrence. The Biograph Vision 600™ from Siemens Healthineers enables a better understanding of disease progression and treatment resistance, to define treatments that can be precisely tailored for patients.

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, “Our patient centric ethos has always motivated us to invest in the best available for our patients and Apollo has been at the forefront of introducing cutting edge technologies in India and the region. Apollo Proton Cancer Centre in Chennai has ushered new hope for over 3.5 billion people, who earlier would have had to travel to the western world to access Proton Therapy, the world’s most advanced radiation therapy. Increasingly Proton Therapy is becoming the standard of care for several cancers and its unique edge of minimal side effects is transforming quality of cancer survivorship.”

Speaking about the benefits, Ms. Suneeta Reddy, Managing Director, Apollo Hospitals added, “The DNA of Apollo Hospitals is clinical excellence and achieving clinical outcomes on par with the world’s best centres. Each of our investments including the Siemens Biograph Vision 600 ™ at our new Apollo Proton Cancer Centre underscores this spirit and commitment to provide an international standard of care for our patients.”